Emerging transmitted drug resistance in treatment-nave human immunodeficiency virus-1 CRF06-cpx-infected patients in Estonia

Scandinavian Journal of Infectious Diseases

Volumn 43, Issue 2, 2011, Pages 122-128

  Avi, Radko ^a   Huik, Kristi ^a   Pauskar, Merit ^a   Ustina, Valentina ^b   Karki, Tonis ^a   Krispin, Tonu ^a   Ainsalu, Klliki ^c   Paap, Piret ^d   Schmidt, Jelena ^e   Nikitina, Natalia ^e   Lutsar, Irja ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b WEST TALLINN CENTRAL HOSPITAL   (Estonia)

^c TARTU UNIVERSITY HOSPITAL   (Estonia)

^d Hospital of Tartu Prison   (Estonia)

^e Ida Viru Central Hospital   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; GENOMIC RNA; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; ESTONIA; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; ESTONIA; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; RECOMBINATION, GENETIC; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

EID: 78751480381     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2010.526956     Document Type: Article

References (31)

1. SPREAD programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008; 22:625-35
2. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009;200:1503-8
3. Yerly S, Junier T, Gayet-Ageron A, Amari EB, von Wyl V, Günthard HF, Hirschel B, Zdobnov E, Kaiser L; Swiss HIV Cohort Study. The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection AIDS 2009;23:1415-23
4. Rumyantseva OA, Olkhovskiy IA, Malysheva MA, Ruzaeva LA, Vasiliev AV, Kazennova EV, et al. Epidemiological networks and drug resistance of HIV type 1 in Krasnoyarsk region, Russia. AIDS Res Hum Retroviruses 2009;25:931-6
5. Santoro MM, Ciccozzi M, Alteri C, Montieri S, Alexiev I, Dimova I, et al. Characterization of drug-resistance mutations in HIV type 1 isolates from drug-na ï ve and ARV-treated patients in Bulgaria. AIDS Res Hum Retroviruses 2008; 24:1133-8
6. Zarandia M, Tsertsvadze T, Carr JK, Nadai Y, Sanchez JL, Nelson AK. HIV-1 genetic diversity and genotypic drug susceptibility in the Republic of Georgia. AIDS Res Hum Retro viruses 2006;22:470-6
7. Nabatov AA, Kravchenko ON, Lyulchuk MG, Shcherbinskaya AM, Lukashov VV. Simultaneous introduction of HIV type 1 subtype A and B viruses into injecting drug users in southern Ukraine at the beginning of the epidemic in the former Soviet Union. AIDS Res Hum Retroviruses 2002;18:891-5
8. Uuskula A, Kalikova A, Zilmer K, Tammai L, DeHovitz J The role of injection drug use in the emergence of human immunodeficiency virus infection in Estonia. Int J Infect Dis 2002;6:23-7
9. Zetterberg V, Ustina V, Liitsola K, Zilmer K, Kalikova N, Sevastianova K, et al. Two viral strains and a possible novel recombinant are responsible for the explosive injecting drug use-associated HIV type 1 epidemic in Estonia. AIDS Res Hum Retroviruses 2004;20:1148-56
10. Liitsola K, Holm K, Bobkov A, Pokrovsky V, Smolskaya T, Leinikki P, et al. An AB recombinant and its parental HIV type 1 strains in the area of the former Soviet Union: low requirements for sequence identity in recombination UNAIDS Virus Isolation Network. AIDS Res Hum Retroviruses 2000;16:1047-53
11. Liitsola K, Tashkinova I, Laukkanen T, Korovina G, Smolskaja T, Momot O, et al. HIV-1 genetic subtype A/B recombinant strain causing an explosive epidemic in injecting drug users in Kaliningrad. AIDS 1998;12:1907-19
12. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drugresistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-9
13. Ustina V, Zilmer K, Tammai L, Raukas M, Andersson A, Lilja E, et al. Epidemiology of HIV in Estonia. AIDS Res Hum Retroviruses 2001;17:81-5
14. A dojaan M, Kivisild T, Mannik A, Krispin T, Ustina V, Zilmer K, et al. Predominance of a rare type of HIV-1 in Estonia. J Acquir Immune Defic Syndr 2005;39:598-605
15. Avi R, Huik K, Sadam M, Karki T, Krispin T, Ainsalu K, et al. Absence of genotypic drug resistance and presence of several naturally occurring polymorphisms of human immunodeficiency virus-1 CRF06-cpx in treatment-na ï ve patients in Estonia. J Med Virol 2009;81:953-8
16. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007;24:1596-9
17. Liitsola K, Laukkanen T, Denisova A, Grishkevichius A, Smolskaja T, Ustina V, et al. Genetic characterization of HIV-1 strains in the Baltic countries and Russia. Scand J Infect Dis 1996;28:537-41
18. Wensing AM, Boucher CA. Worldwide transmission of drugresistant HIV. AIDS Rev 2003;5:140-55
19. Booth CL, Garcia-Diaz AM, Youle MS, Johnson MA, Phillips A, Geretti AM. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 2007;59:517-24
20. Hurt CB, McCoy SI, Kuruc J, Nelson JA, Kerkau M, Fiscus S, et al. Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir Ther 2009;14:673-8
21. Stanczak GP, Stanczak JJ, Marczynska M, Firlag-Burkacka E, Wiercinska-Drapalo A, Leszczyszyn-Pynka M, et al. Evolving patterns of HIV-1 transmitted drug resistance in Poland in the years 2000 - 2008. J Med Virol 2010;82:1291-4
22. Babic DZ, Zelnikar M, Seme K, Vandamme AM, Snoeck J, Tomazic J, et al. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-na ï ve patients in Slovenia, 2000 - 2004. Virus Res 2006;118:156-63
23. Ciccozzi M, Gori C, Boros S, Ruiz-Alvarez MJ, Harxhi A, Dervishi M, et al. Molecular diversity of HIV in Albania. J Infect Dis 2005;192:475-9
24. Juhasz E, Ghidan A, Kemeny B, Nagy K. Emergence of antiretroviral drug resistance in therapy-na ï ve HIV infected patients in Hungary. Acta Microbiol Immunol Hung 2008;55:383-94
25. Kanizsai S, Ghidan A, Ujhelyi E, Banhegy D, Nagy K. Monitoring of drug resistance in therapy-na ï ve HIV infected patients and detection of African HIV subtypes in Hungary Acta Microbiol Immunol Hung 2010;57:55-68
26. Kolupajeva T, Aldins P, Guseva L, Dusacka D, Sondore V, Viksna L, et al. HIV drug resistance tendencies in Latvia Cent Eur J Public Health 2008;16:138-40
27. Paraschiv S, Otelea D, Dinu M, Maxim D, Tinischi M. Polymorphisms and resistance mutations in the protease and reverse transcriptase genes of HIV-1 F subtype Romanian strains. Int J Infect Dis 2007;11:123-8
28. Vinogradova A, Gafurova E, Munoz-Nieto M, Rakhmanova A, Osmanov S, Thomson MM. Short communication: Molecular epidemiology of HIV type 1 in the Republic of Dagestan, Russian Federation: virtually uniform circulation of subtype A, former Soviet Union variant, with predominance of the V77I(PR) subvariant. AIDS Res Hum Retroviruses 2010;26:395-400
29. Ferdats A, Konicheva V, Dievberna I, Lilja E, Albert J. An HIV type 1 subtype A outbreak among injecting drug users in Latvia. AIDS Res Hum Retroviruses 1999;15:1487-90
30. Novitsky VA, Montano MA, Essex M. Molecular epidemiology of an HIV-1 subtype A subcluster among injection drug users in the Southern Ukraine. AIDS Res Hum Retroviruses 1998;14:1079-85
31. Saad MD, Shcherbinskaya AM, Nadai Y, Kruglov YV, Antonenko SV, Lyullchuk MG, et al. Molecular epidemiology of HIV type 1 in Ukraine: birthplace of an epidemic. AIDS Res Hum Retroviruses 2006;22:709-14